Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trifolium pratense ethanolic extract (TPEE) is a botanical extract derived from red clover (*Trifolium pratense L.*), a member of the Fabaceae family. It is characterized by a high concentration of isoflavones, such as formononetin, biochanin A, genistein, and daidzein, which act as phytoestrogens by binding to estrogen receptors alpha (ERα) and beta (ERβ). TPEE is primarily utilized as an over-the-counter herbal remedy for the management of menopausal symptoms and has been investigated for its effects on serum lipid profiles, gut microbiota, and cardiovascular health. Additionally, research has explored its potential chemopreventive properties in breast cancer, where it demonstrates biphasic effects on cell proliferation and oxidative stress modulation. It is also used in veterinary contexts as an anticoccidial agent in poultry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trifolium pratense ethanolic extract.